Notice 21 Aug 2025 securities, nyse, transparency, financial regulation, market strategy, auction prices

📈NYSE Texas Proposes Rule Change on Auction Price Calculations

The NYSE Texas has filed a proposed rule change to amend Rule 7.35, enhancing how Auction Reference Prices are calculated during auctions. This aims to reflect more accurate market conditions and price movements, promoting transparency and better functioning of sales in auction processes on the exchange. The changes could impact trading practices significantly.

Learn More
Notice 21 Aug 2025 compliance, usda, regulation, construction, seismic safety

🏗️Notice on Seismic Safety Requirements for New Building Construction

In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended), the United States Department of Agriculture (USDA) Rural Utilities Service (RUS) announces its' intention to request an extension of a currently approved information collection and invites comments on this information collection.

Learn More
Notice 21 Aug 2025 compliance, arizona, business regulation, repatriation, nagpra, cultural heritage

📜Notice of Inventory Completion & Repatriation in Arizona

In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the U.S. Department of the Interior, Bureau of Land Management, Arizona State Office (BLM Arizona State Office) has completed an inventory of human remains and has determined that there is a cultural affiliation between the human remains and Indian Tribes or Native Hawaiian organizations in this notice.

Learn More
Proposed Rule 21 Aug 2025 compliance, regulations, aviation, faa, safety, aircraft, aviation safety, incorporation by reference, air transportation, helicopter, transport, airworthiness

🚁Proposed Airworthiness Directive for Airbus Helicopters by FAA

The FAA proposes to supersede Airworthiness Directive (AD) 2021-20-16, which applies to all Airbus Helicopters Model AS355E, AS 355-F, AS 355-F1, AS355F2, AS355N, and AS355NP helicopters and certain Model AS 350B3 helicopters. AD 2021-20-16 requires repetitive cleaning and visual and detailed inspections of the right-hand side of the vertical fin spar and vertical fin upper attachments for discrepancies (cracking) with corrective action, if necessary. Since the FAA issued AD 2021-20-16, Airbus Helicopters developed a modification of the upper fin assembly. This proposed AD would require the same actions as AD 2021-20-16 and would also require replacement of the upper fin assembly with a modified upper fin assembly, which would constitute terminating action for the repetitive inspections. The FAA is proposing this AD to address the unsafe condition on these products.

Learn More
Notice 21 Aug 2025 agriculture, regulatory, trade, united states, export, antitrust, rice, uk, eu

🌾Amended Export Trade Certificate of Review for Rice Quotas Issued

The Secretary of Commerce, through the Office of Trade and Economic Analysis (OTEA), issued an amended Export Trade Certificate of Review to the Association for the Administration of Rice Quotas, Inc. on July 9, 2025.

Learn More
Notice 21 Aug 2025 compliance, agriculture, labor, employment regulation, migratory workers

🌾Comment Request on Agricultural Recruitment System Forms

The Department of Labor's (DOL) Employment and Training Administration (ETA) is soliciting comments concerning proposed revisions to the information collection request (ICR) entitled, "Agricultural Recruitment System Forms Affecting Migratory Farm Workers" (Office of Management and Budget (OMB) Control Number 1205- 0134). This comment request is part of continuing Departmental efforts to reduce paperwork and respondent burden in accordance with the Paperwork Reduction Act of 1995 (PRA).

Learn More
Notice 21 Aug 2025 compliance, import regulations, controlled substances, drug enforcement, cambrex high point

📦Cambrex High Point's Application for Controlled Substances Import

Cambrex High Point, Inc., has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 21 Aug 2025 compliance, regulation, uspto, patent, trademark, invention promoters

📄USPTO Seeks Comments on Invention Promoters Complaint Process

The United States Patent and Trademark Office (USPTO) will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on this information collection renewal of 0651-0044 (Complaints Regarding Invention Promoters), which helps the USPTO assess the impact of its information collection requirements and minimize the public's reporting burden. Public comments were previously requested via the Federal Register on May 19, 2025, during a 60-day comment period (90 FR 21295) This notice allows for an additional 30 days for public comment.

Learn More
Notice 21 Aug 2025 compliance, regulations, pharmaceutical, importation, controlled substances, drug enforcement

💊Vici Health Sciences' Import Application for Controlled Substances

Vici Health Sciences, LLC. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Rule 21 Aug 2025 compliance, healthcare, fda, medical devices, orthopedic devices

🦴FDA Classifies Orthopedic Surgical Instruments as Class II Devices

The Food and Drug Administration (FDA, the Agency, or we) is classifying orthopedic manual surgical instrumentation for use with total disc replacement devices into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of orthopedic manual surgical instrumentation for use with total disc replacement devices. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Learn More